M. Carmen Mir, MD, PhD

home / authors / m-carmen-mir-md-phd

Articles

A panel of 4 experts on bladder cancer seated at a long table

Key Takeaways on Evolving Bladder Cancer Treatment Landscape

Axel Merseburger, MD, PhD;M. Carmen Mir, MD, PhD;Shilpa Gupta, MD, Cleveland Clinic;Neal Shore, MD, FACS
December 21st 2023

The expert panel concludes its discussion by providing key takeaways on the evolving bladder cancer treatment landscape following ESMO 2023.

Read More

A panel of 4 experts on bladder cancer seated at a long table

Approach to Collaborative Care in Bladder Cancer

Axel Merseburger, MD, PhD;M. Carmen Mir, MD, PhD;Shilpa Gupta, MD, Cleveland Clinic;Neal Shore, MD, FACS
December 21st 2023

The panel discusses the Large Urology Group Practice Association and provides insights on collaborative care approaches in bladder cancer.

Read More

A panel of 4 experts on bladder cancer seated at a long table

Enfortumab Vedotin and the Role of ADCs in Bladder Cancer

Axel Merseburger, MD, PhD;M. Carmen Mir, MD, PhD;Shilpa Gupta, MD, Cleveland Clinic;Neal Shore, MD, FACS
December 15th 2023

Bladder cancer specialists discuss enfortumab vedotin and the role of antibody-drug conjugates in the treatment landscape.

Read More

A panel of 4 experts on bladder cancer seated at a long table

Bladder Cancer: Highlights from ESMO 2023 and Ongoing Developments

Axel Merseburger, MD, PhD;M. Carmen Mir, MD, PhD;Shilpa Gupta, MD, Cleveland Clinic;Neal Shore, MD, FACS
December 15th 2023

The expert panel reviews highlights from ESMO 2023 and discusses ongoing developments in the treatment landscape for bladder cancer.

Read More

A panel of 4 experts on bladder cancer seated at a long table

Bladder Cancer: Treatment Options and Managing Adverse Effects

Axel Merseburger, MD, PhD;M. Carmen Mir, MD, PhD;Shilpa Gupta, MD, Cleveland Clinic;Neal Shore, MD, FACS
December 7th 2023

Comprehensive insights on treatment considerations and managing immunotherapy-related adverse effects for patients with bladder cancer.

Read More

A panel of 4 experts on bladder cancer seated at a long table

Monitoring Patients With NMIBC

Axel Merseburger, MD, PhD;M. Carmen Mir, MD, PhD;Shilpa Gupta, MD, Cleveland Clinic;Neal Shore, MD, FACS
December 7th 2023

The panel discusses strategies for monitoring patients with non–muscle invasive bladder cancer and the potential role of biomarkers.

Read More

A panel of 4 experts on bladder cancer seated at a long table

Treatment Considerations and Role of Trimodal Therapy in Bladder Cancer

Axel Merseburger, MD, PhD;M. Carmen Mir, MD, PhD;Shilpa Gupta, MD, Cleveland Clinic;Neal Shore, MD, FACS
November 30th 2023

Expert perspectives on treatment options available for patients with bladder cancer and the role of trimodal therapy.

Read More

A panel of 4 experts on bladder cancer seated at a long table

Overview of Non–Muscle Invasive Bladder Cancer (NMIBC)

Axel Merseburger, MD, PhD;M. Carmen Mir, MD, PhD;Shilpa Gupta, MD, Cleveland Clinic;Neal Shore, MD, FACS
November 30th 2023

A panel of experts on bladder cancer provide an overview of the stratification, natural history, and treatment of bladder cancer.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need